Eli Lilly enters coverage as the most dominant franchise in large-cap healthcare and one of the least forgiving valuations. The verdict is Watchlist. At $1,184.78, the probability-weighted fair value of $1,213 leaves about 2% of upside, and the name becomes interesting near $1,050.

The bull case

The numbers are extraordinary. Second-quarter revenue rose 48% to $23.0 billion, beating consensus by 11%, and adjusted EPS of $8.38 beat by 27%. Mounjaro and Zepbound, both built on tirzepatide, sold $14.9 billion between them, and Lilly writes about six of every ten US obesity prescriptions. Full-year revenue guidance rose to $85-87 billion, and the implied second half still looks conservative against the current run-rate.

The pipeline extends the story. Retatrutide delivered up to 20.8% weight loss at 80 weeks in patients with type 2 diabetes, and Lilly plans to file in the first quarter of 2027. The FDA also approved Onswik, the first once-weekly basal insulin in the US, on 24 September. In the bull scenario, US price cuts slow, the Foundayo pill reaches about $6 billion in 2027 sales and the stock earns 30 times earnings, which points to $1,545.

The bear case

Growth now comes from volume, while price moves the other way. Medicare’s GLP-1 Bridge began on 1 July at $50 a month to patients, self-pay pricing runs $299-449, and the CFO put the underlying US price decline at 9% in the quarter. Tirzepatide is 65% of revenue, so each further five points of US price erosion costs roughly $1.50 of annual EPS.

The oral launch is also behind. Foundayo sold $98 million in its first full quarter, short of expectations, while Novo Nordisk’s Wegovy pill sold about $494 million. Lilly has reportedly spent more than $20 billion on acquisitions this year, more than its trailing free cash flow, and its CEO has signalled larger deals ahead. Add a ten-year Treasury yield near its highest since 2007, and the bear scenario of 21 times $41 of 2027 EPS gives $861.

Where that leaves the stock

The base case of $47 in 2027 EPS at 26 times gives $1,222, close to today’s price. That makes the setup roughly symmetric for a stock priced for the good outcome. The first test comes with third-quarter results, expected in late October or early November, which should show whether US price erosion is narrowing and whether Foundayo volume is accelerating.

The scenario table, sizing of each development and full scorecard are in the complete Eli Lilly and Company (LLY) report on our Reports page.